Drug Research
Global market will reach $26 billion by 2020, says GBI Research
The global market for drug delivery technologies will rise from $20 billion in 2015 to around $26 billion by 2020, according to business intelligence firm GBI Research. The company’s latest report states that the emergence of...
Drug Research
Neos Therapeutics Submits NDA for Amphetamine Extended-Release Liquid Suspension Drug Candidate, Amphetamine, for the Treatment of ADHD
Neos Therapeutics a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit hyperactivity disorder (ADHD), announced that it has submitted a NDA to the U.S. FDA for its Amphetamine...
Drug Research
Ra Pharmaceuticals Receives Orphan Drug Designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
Ra Pharmaceuticals , a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for diseases of complement dysregulation, announced that the EC has designated RA101495 as an orphan medicinal product for the treatment of paroxysmal nocturnal hemoglobinuria...
Drug Research
BioSpecifics Technologies Corp. Announces Positive Data from Phase 2b Study of CCH in Patients with Cellulite
BioSpecifics Technologies Corp , a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. And Xiapex® in...
Drug Research
Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug Targets and Bioactive Molecules
Bristol-Myers Squibb Company and Enterome, a pioneer in the development of pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for the discovery and development of microbiome-derived biomarkers, drug...
Drug Research
Cytori Granted FDA Orphan Drug Designation for ECCS-50 in Scleroderma
Cytori Therapeutics, Inc. announced that the US FDA Office of Orphan Products Development (OOPD) has granted Cytori an orphan drug designation for cryopreserved or centrally processed ECCS-50 for scleroderma. “This orphan drug designation is part of...
Drug Research
Bristol-Myers Squibb Enters into New Collaboration with Johns Hopkins Focused on Immuno-Oncology Research
Bristol-Myers Squibb Company announced that the company has entered into a five-year research collaboration with the Johns Hopkins University. The collaboration is designed to identify mechanisms of response and resistance in patients whose cancer is being...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
